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Many laboratory strains of Escherichia coli are resistant to methotrexate (MTX), a folate analogue that binds
dihydrofolate reductase (DHFR). Mutations that inactivate either tolC or acrA confer MTX sensitivity. Further,
overexpression of a fusion protein with DHFR activity reverses this sensitivity by titrating out intracellular
MTX. These results suggest that MTX accumulates in cells where mutations in acrA or tolC have inactivated
the TolC-dependent AcrAB multidrug resistance efflux pump.
Methotrexate (MTX) is a folate analogue that inhibits the
activity of dihydrofolate reductase (DHFR) (16), which cata-
lyzes the NADPH-dependent reduction of dihydrofolate to
tetrahydrofolate. Reduced folates are substrates in a number
of one-carbon transfers in purine, pyrimidine, and amino acid
biosynthesis (3). Inhibition of DHFR activity initially results in
the depletion of N5,N10-methylene tetrahydrofolate, followed
by inhibition of DNA synthesis and ultimately cell death (8).
DHFR is thus a well-studied target of antibiotic and antineo-
plastic therapy.
Although MTX binds both human and Escherichia coli
DHFR very tightly, with Ki values of 3.4 and 1.0 pM, respec-
tively (2), all of the E. coli isolates we tested (genotypes of the
strains used in this study are listed in Table 1), which included
both common laboratory strains (MG1655, MC4100, AG1688,
and ZK126) and clinical isolates (O157:H7, RM74A, STM1,
LL, RM52B, DD, and RM33B), were resistant to MTX added
to solid medium at concentrations of up to 1 mM, the highest
concentration we tested (data not shown).
Antibiotic resistance can occur by a variety of mechanisms,
including failure of the drug to bind its target, overexpression
of the drug target, modification or degradation of the drug,
creation of permeability barriers, or active export of the drug.
It is increasingly recognized that active efflux plays a major role
in the resistance of many organisms to a plethora of agents (11,
20). A wide variety of antibiotics are exported from E. coli by
one of several active efflux systems (11, 12, 19, 20). At least two
of these systems, the AcrAB and EmrAB efflux pumps, have
been shown to depend on the outer membrane protein TolC
(1, 7, 12, 19, 20).
To determine whether the MTX resistance was due to a
TolC-dependent efflux pump, we examined the effect of a
tolC::Tn10 mutation. LBB1175, in which tolC had been inac-
tivated by the Tn10 insertion, was sensitive to 1 mM MTX,
while W4573, the isogenic TolC1 control, was resistant. Simi-
lar results were obtained using the common laboratory strain
MG1655, which is the reference wild-type E. coli K-12 strain
used for the genome sequence (4), and AG1688 (see below).
Strains carrying Tn10 at a different chromosomal location re-
mained resistant to MTX. These results suggest that MTX
resistance is mediated by a TolC-containing multidrug resis-
tance efflux pump (MDR).
tolC mutants are pleiotropic (17, 26) and are hypersensitive
to many hydrophobic agents (18). Thus, the loss of MTX re-
sistance in the tolC mutant might not be due to the loss of
function of an MDR. To address this possibility, we tested the
effects of mutations that inactivate specific TolC-dependent
MDRs. The AcrAB pump belongs to the RND (for resistance,
nodulation, and division) family, and its substrates include
sodium dodecyl sulfate, basic dyes, novobiocin, and tetracy-
cline (19, 20); the EmrAB pump belongs to the MF (major
facilitator) family, and its substrates include carbonyl cyanide
m-chlorophenylhydrazone, nalidixic acid, and phenyl mercury
acetate (19, 20). A strain containing the acrA1 mutation
(N43) was sensitive to 1 mM MTX, while its isogenic parent
(W4573) was resistant. In contrast, both the emrB mutant
(OLS103) and its isogenic parent (AMS6) were MTX resis-
tant. These results show that the MTX sensitivity of the tolC
strains is at least partly due to inactivation of the AcrAB
MDR, while the EmrAB pump does not have a major role in
MTX export.
MICs of MTX were determined for a set of isogenic E. coli
strains containing combinations of acrA, emrB, and tolC mu-
tations (Table 2). The wild-type strain (W4573) was resistant to
1,024 mM MTX, the highest concentration tested. The emrB
mutation did not affect the MIC, either alone (compare W4573
to SK636) or in combination with acrA1 (compare N43 to
SK627) or tolC::Tn10 (compare SK642 to SK660). Inactivation
of either acrA or tolC resulted in a decrease of the MTX MIC
to 256 or 64 mM, respectively. Since the acrA1 allele is an IS2
insertion in the second codon of acrA (14), it is unlikely that
the remaining MTX resistance in the acrA1 mutant is due to
residual activity of the acrA gene product. The tolC gene prod-
uct seems to have more than one role in MTX resistance. It is
unclear if this is due to the loss of function of another, uniden-
tified TolC-containing MDR or the highly pleiotropic effects of
tolC mutations on outer membrane structure (17, 26). Similar
alterations have not been found in the outer membrane of acr
mutants (19, 21, 24).
The additional role of TolC is not related to the EmrAB
MDR, since the acrA1 emrB double mutation (in SK627)
yielded an MIC identical to that yielded by the acrA1 single
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mutation. Similar combinations of mutations in a different
background (AG1688) yielded identical MICs (data not shown).
This further demonstrates that the observed effects are not
strain specific.
To determine whether inhibition of DHFR was sufficient to
explain the MTX sensitivity of tolC strains, we examined
whether the MTX sensitivity of AG1688 tolC::Tn10 (SK037)
could be suppressed by overexpression of DHFR activity. In
the course of other (unpublished) studies, we had constructed
a plasmid, pSK029, which expresses a fusion protein, cI-
DHFR, in which the N-terminal DNA binding domain of the
bacteriophage l repressor is fused to E. coli DHFR; the fusion
protein is expressed under the control of the lacUV5 pro-
moter. Neither pSK029 nor pXZ020, a control plasmid ex-
pressing cI-GCN4 (a fusion to the leucine zipper of GCN4),
affected the MTX resistance of wild-type AG1688 whether or
not the fusion proteins were overexpressed (Table 3, lines 3
and 5). AG1688 tolC::Tn10 strains containing either plasmid
were sensitive to MTX under conditions in which the fusion
proteins were uninduced (Table 3, lines 4 and 6). However, in
the presence of isopropyl-b-D-thiogalactopyranoside (IPTG),
which induces the overexpression of cI-DHFR, SK029
tolC::Tn10 was resistant to high concentrations of MTX (Table
3, line 4). In contrast, IPTG-induced overexpression of the
control protein cI-GCN4 had no protective effect on the tolC
strain (Table 3, line 6).
These results show that MTX sensitivity in the tolC strain is
due to the inhibition of endogenous DHFR by the drug. When
cI-DHFR is overexpressed, the DHFR activity provided by the
DHFR domain in the fusion protein cannot be titrated out,
which strongly suggests that the plasmid-coded DHFR acts to
sequester MTX that is added to the medium. Increasing the
level of DHFR should not relieve sensitivity due to mecha-
nisms that do not involve uptake of MTX.
The results of this study can be summarized as follows.
(i) All of the TolC1 AcrA1 strains of E. coli we tested were
resistant to at least 1 mM MTX when grown on solid medium
containing the drug. (ii) MTX resistance is decreased by mu-
tations that disrupt tolC or acrA, genes that code for integral
components of the AcrAB MDR, suggesting that resistance is
due to active export of MTX via the AcrAB MDR. (iii) Mu-
tation of the emrB gene does not decrease MTX resistance,
suggesting that MTX is not a substrate of this MDR. (iv) The
difference between the MICs for tolC::Tn10 and acrA::IS2
TABLE 2. Sensitivities of acrA, tolC, and emrB
mutants to MTX
Strain Relevant genotypea MICb of MTX (mM)
W4573 Wild type .1,024
SK636 emrB .1,024
N43 acrA1 256
SK627 acrA1 emrB 256
LBB1175 tolC 64
SK642 acrA1 tolC 64
SK660 acrA1 tolC emrB 64
a For a full listing of genotypes, see Table 1.
b MICs were determined by examining the growth of 2-ml liquid cultures
containing twofold serial dilutions of MTX (2 to 1,024 mM) in Luria-Bertani
liquid broth. The inoculum (20 ml) contained approximately 105 cells per ml.
The MIC was determined as the lowest concentration that prevented visible
growth after 8 h on a roller drum at 37°C. All the tested strains grew to satura-
tion in the absence of MTX. The values are the averages of three separate ex-
periments.
TABLE 1. E. coli strains used
Strain Genotype Reference and/or source
MG1655 K-12 F2 l2 22; D. Siegele
MC4100 F2 araD139 D(argF-lac)U169 rpsL150 relA1 deoC1 rbsR
flhD5301 fruA25 l2
5; D. Siegele
AG1688 F9128 lacIq lacZ::Tn5/araD139 D(ara-leu)7697 D(lac)X74
galE15 galK16 rpsL(Strr) hsdR2 mcrA mcrB1
MC1061 F9128 lacIq lacZ::Tn5 (9)
ZK126 W3110 D(lac)U169 tna-2 6; D. Siegele
O157:H7 E. coli isolate from human 10; D. Siegele
RM74A Group I E. coli from human female 15; D. Siegele
STM1 Group I E. coli from human male 27; D. Siegele
LL Group II E. coli from human infant 23; D. Siegele
RM52B Group II E. coli from human female 15; D. Siegele
DD Group III E. coli from human infant 27; D. Siegele
RM33B Group III E. coli from human female 15; D. Siegele
W4573 K-12 F2 lac ara mal xyl mtl gal rpsL 14; J. A. Fralick
LBB1175 W4573 tolC::Tn10 J. A. Fralick
N43 W4573 acrA1 14; J. A. Fralick
OLS103 AMS6 emrB::Km 13; J. A. Fralick
AMS6 K-12 F2 DlacU169 13; J. A. Fralick
SK627 W4573 acrA1 emrB::Km N43 3 P1 vir (OLS103)
SK636 W4573 emrB::Km W4573 3 P1 vir (OLS103)
KH803 MC4100 tolC::Tn10 R. Young
SK642 W4573 acrA1 tolC::Tn10 N43 3 P1 vir (KH803)
SK660 W4573 acrA1 emrB::Km tolC::Tn10 SK627 3 P1 vir (KH803)
SK037 AG1688 tolC::Tn10 AG1688 3 P1 vir (KH803)
SK029 AG1688(pSK029) pSK029, a pBR322-derived plasmid that expresses a l cI-E. coli
DHFR fusion protein from PlacUV5, was introduced by M13-mediated
transduction (25) into AG1688
XZ020 AG1688(pXZ020) pXZ020, a pBR322-derived plasmid that expresses a l cI-GCN4
leucine zipper fusion protein from PlacUV5, was introduced by
M13-mediated transduction into AG1688











strains suggests the possibility of another mechanism for low-
level TolC-dependent MTX resistance.
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TABLE 3. Suppression of the MTX sensitivities of TolC mutants by cI-DHFR
Line Strainb Fusion protein tolC genotype
Growtha
2IPTG 1IPTG
2MTX 1MTX 2MTX 1MTX
1 AG1688 None tolC1 1 1 1 1
2 SK037 None tolC mutant 1 2 1 2
3 SK029 cI-DHFR tolC1 1 1 1 1
4 SK029 tolC::Tn10 cI-DHFR tolC mutant 1 2 1 1
5 XZ020 cI-GCN4 tolC1 1 1 1 1
6 XZ020 tolC::Tn10 cI-GCN4 tolC mutant 1 2 1 2
a Cultures were grown to saturation in Luria-Bertani broth at 37°C overnight and diluted in M9 salts to approximately 5,000 CFU/ml. A total of 10 ml of each diluted
culture was pipetted onto Luria-Bertani agar plates containing no IPTG (2IPTG) or 1 mM IPTG (1IPTG) and either no MTX (2MTX) or 1 mM MTX (1MTX)
as indicated. The spots were allowed to dry and then the plates were incubated at 37°C overnight. 1, growth; 2, no growth. The observations are from at least three
separate experiments.
b tolC::Tn10 was introduced into the indicated strains by P1 vir transduction using KH803 as the donor.
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